CA2088593A1 - Utilisation des metalloporphyrines comme agents de potentialisation de la therapie antisida - Google Patents

Utilisation des metalloporphyrines comme agents de potentialisation de la therapie antisida

Info

Publication number: CA2088593A1
Authority: CA; Canada
Prior art keywords: heme; azt; treatment; acid addition; hiv
Prior art date: 1990-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002088593A

Other languages

English (en)

Inventor

Attallah Kappas

Richard D. Levere

Nader G. Abraham

Doris J. Bucher

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rockefeller University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-31

Filing date

1991-07-25

Publication date

1992-02-01

1991-07-25 Application filed by Individual filed Critical Individual

1992-02-01 Publication of CA2088593A1 publication Critical patent/CA2088593A1/fr

Status Abandoned legal-status Critical Current

Links

238000002560 therapeutic procedure Methods 0.000 title description 5
230000003389 potentiating effect Effects 0.000 title description 2
150000003278 haem Chemical class 0.000 claims abstract description 58
239000000203 mixture Substances 0.000 claims abstract description 29
239000003814 drug Substances 0.000 claims abstract description 28
229940079593 drug Drugs 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 17
102000003951 Erythropoietin Human genes 0.000 claims abstract description 16
108090000394 Erythropoietin Proteins 0.000 claims abstract description 16
229940105423 erythropoietin Drugs 0.000 claims abstract description 16
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 16
206010038997 Retroviral infections Diseases 0.000 claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
230000000798 anti-retroviral effect Effects 0.000 claims abstract description 6
238000011282 treatment Methods 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 24
150000003839 salts Chemical class 0.000 claims description 18
-1 organometallic porphyrins Chemical class 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 16
208000031886 HIV Infections Diseases 0.000 claims description 8
230000036436 anti-hiv Effects 0.000 claims description 8
208000037357 HIV infectious disease Diseases 0.000 claims description 7
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
238000007911 parenteral administration Methods 0.000 claims description 6
LLDZJTIZVZFNCM-UHFFFAOYSA-J 3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;dichlorotin(2+) Chemical compound [H+].[H+].[Cl-].[Cl-].[Sn+4].[N-]1C(C=C2C(=C(C)C(=CC=3C(=C(C)C(=C4)N=3)CC)[N-]2)CCC([O-])=O)=C(CCC([O-])=O)C(C)=C1C=C1C(C)=C(CC)C4=N1 LLDZJTIZVZFNCM-UHFFFAOYSA-J 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 5
230000002411 adverse Effects 0.000 claims description 5
230000002441 reversible effect Effects 0.000 claims description 5
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 4
229940059489 heme arginate Drugs 0.000 claims description 4
229950003776 protoporphyrin Drugs 0.000 claims description 4
239000008177 pharmaceutical agent Substances 0.000 claims 13
239000007864 aqueous solution Substances 0.000 claims 11
230000006229 amino acid addition Effects 0.000 claims 2
208000030507 AIDS Diseases 0.000 abstract description 23
208000036142 Viral infection Diseases 0.000 abstract description 3
230000009385 viral infection Effects 0.000 abstract description 3
UVBCRFAFWVSXOL-JGVFFNPUSA-N 3-azido-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N(N=[N+]=[N-])C(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 UVBCRFAFWVSXOL-JGVFFNPUSA-N 0.000 description 78
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 41
229940025294 hemin Drugs 0.000 description 41
241000725303 Human immunodeficiency virus Species 0.000 description 31
210000004027 cell Anatomy 0.000 description 16
230000010076 replication Effects 0.000 description 10
241000700605 Viruses Species 0.000 description 8
230000000840 anti-viral effect Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
239000012091 fetal bovine serum Substances 0.000 description 7
239000002777 nucleoside Substances 0.000 description 7
238000003556 assay Methods 0.000 description 6
210000002960 bfu-e Anatomy 0.000 description 6
210000003013 erythroid precursor cell Anatomy 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000011324 bead Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
125000003835 nucleoside group Chemical group 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
241001430294 unidentified retrovirus Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
230000000925 erythroid effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
150000004032 porphyrins Chemical group 0.000 description 4
206010001513 AIDS related complex Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000011135 tin Substances 0.000 description 3
229910052718 tin Inorganic materials 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
241000714165 Feline leukemia virus Species 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
241000714223 Rauscher murine leukemia virus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
229940124411 anti-hiv antiviral agent Drugs 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
230000003253 viricidal effect Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
208000012124 AIDS-related disease Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000182988 Assa Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000713838 Avian myeloblastosis virus Species 0.000 description 1
206010051779 Bone marrow toxicity Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000008015 Hemeproteins Human genes 0.000 description 1
108010089792 Hemeproteins Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000714192 Human spumaretrovirus Species 0.000 description 1
BUNNSNWDQSGONB-KXUUBAJSSA-N IN1C=2C=CC1=CC=1C=CC(=CC3=CC(=C(N3I)C=C3C=CC(C2)=N3)[2H])N1.[Sn] Chemical compound IN1C=2C=CC1=CC=1C=CC(=CC3=CC(=C(N3I)C=C3C=CC(C2)=N3)[2H])N1.[Sn] BUNNSNWDQSGONB-KXUUBAJSSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
241000713675 Spumavirus Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000010094 Visna Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
231100000366 bone marrow toxicity Toxicity 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
150000001869 cobalt compounds Chemical class 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229960005102 foscarnet Drugs 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
206010025382 macrocytosis Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
239000001054 red pigment Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Zoology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002088593A 1990-07-31 1991-07-25 Utilisation des metalloporphyrines comme agents de potentialisation de la therapie antisida Abandoned CA2088593A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US56019190A	1990-07-31	1990-07-31
US560,191		1990-07-31
US73509091A	1991-07-24	1991-07-24
US735,090		1991-07-24

Publications (1)

Publication Number	Publication Date
CA2088593A1 true CA2088593A1 (fr)	1992-02-01

Family

ID=27072276

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002088593A Abandoned CA2088593A1 (fr)	1990-07-31	1991-07-25	Utilisation des metalloporphyrines comme agents de potentialisation de la therapie antisida

Country Status (5)

Country	Link
EP (1)	EP0543902A4 (fr)
JP (1)	JPH05504774A (fr)
AU (1)	AU645131B2 (fr)
CA (1)	CA2088593A1 (fr)
WO (1)	WO1992002242A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994005285A1 (fr) *	1992-09-03	1994-03-17	The Regents Of The University Of California	Compositions de metalloporphyrine
AU1296795A (en) *	1993-12-28	1995-07-17	New York Blood Center, Inc., The	Methods for preventing or treating hiv-1 or hiv-2 infection
TW247876B (en)	1993-12-28	1995-05-21	New York Blood Ct Inc	Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
US5631219A (en) *	1994-03-08	1997-05-20	Somatogen, Inc.	Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en)	1994-03-08	2001-06-05	Somatogen, Inc.	Stabilized compositions containing hemoglobin
EP0939644B1 (fr) *	1996-08-27	2004-01-14	Hemosol Inc.	Stimulation amelioree de l'erythropoiese
AU765856B2 (en) *	1996-08-27	2003-10-02	Hemosol Inc.	Enhanced stimulation of erythropoiesis
US20020072512A1 (en) *	2000-12-08	2002-06-13	Metaphore Pharmaceuticals, Inc	Method of preventing and treating HIV-mediated central nervous system damage
AU2003258604A1 (en) *	2002-03-28	2003-10-13	Exponential Biotherapies, Inc.	Oxygenating agents for enhancing host responses to microbial infections
GB0519169D0 (en)	2005-09-21	2005-10-26	Leuven K U Res & Dev	Novel anti-viral strategy
RU2475498C1 (ru) *	2011-11-17	2013-02-20	Общество С Ограниченной Ответственностью "Фарминтерпрайсез"	Новые производные гемина с антибактериальной и противовирусной активностью

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5049493A (en) *	1987-10-23	1991-09-17	California Institute Of Technology	Enhancement of cell growth by expression of a cloned hemoglobin gene
EP0337598A3 (fr) *	1988-02-26	1991-07-03	Georgia State University Foundation, Inc.	Utilisation de porphyrines et de métalloporphyrines dans le traitement de maladies causées par HIV
US5192788A (en) *	1988-05-23	1993-03-09	Georgia State University Foundation, Inc.	Porphyrin antiviral compositions

1991
- 1991-07-25 EP EP19910915068 patent/EP0543902A4/en not_active Withdrawn
- 1991-07-25 JP JP3514118A patent/JPH05504774A/ja active Pending
- 1991-07-25 CA CA002088593A patent/CA2088593A1/fr not_active Abandoned
- 1991-07-25 WO PCT/US1991/005283 patent/WO1992002242A1/fr not_active Ceased
- 1991-07-25 AU AU84104/91A patent/AU645131B2/en not_active Ceased

Also Published As

Publication number	Publication date
WO1992002242A1 (fr)	1992-02-20
EP0543902A1 (fr)	1993-06-02
EP0543902A4 (en)	1993-10-27
AU645131B2 (en)	1994-01-06
AU8410491A (en)	1992-03-02
JPH05504774A (ja)	1993-07-22

Legal Events

Date	Code	Title	Description
1998-07-22	EEER	Examination request
2001-07-25	FZDE	Discontinued
2023-10-24	FZDE	Discontinued	Effective date: 20010725

Publication	Publication Date	Title
Sommadossi et al.	1988	Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity
Soudeyns et al.	1991	Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
Sarin et al.	1987	Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
Baba et al.	1989	Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
Nakashima et al.	1986	Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro
Montefiori et al.	1991	Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro
Mitsuya et al.	1985	3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Lin et al.	1989	Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol
Coates et al.	1992	The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro
Kageyama et al.	1993	In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine
US5264356A (en)	1993-11-23	Regulating retroviral replication, infection, and pathogenesis
Papadopulos-Eleopulos et al.	1992	Oxidative stress, HIV and AIDS
Bader et al.	1991	Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.
Malley et al.	1994	Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2', 3'-dideoxyinosine in infected resting human lymphocytes.
Kageyama et al.	1992	In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations
AU645131B2 (en)	1994-01-06	Use of metalloporphyrins to potentiate aids therapy
Craig et al.	1993	Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase
HOSHINO et al.	1989	New antifungal antibiotics, benanomicins A and B inhibit infection of T-cell with human immunodeficiency virus (HIV) and syncytium formation by HIV
Turano et al.	1989	Inhibitory effect of papaverine on HIV replication in vitro
Carter et al.	1990	Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
Bryant et al.	1995	SC-52151, a novel inhibitor of the human immunodeficiency virus protease
Richman	1987	Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1
Garg et al.	1992	Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells
Anand et al.	1990	Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement
Davis et al.	1995	Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid CU1+